SCHEMBL22718316

SCHEMBL22718316

COc1ccc(CN(C)S(=O)(=O)c2ccc(Nc3ccc(C(F)(F)F)cn3)c(-c3cn(C4CCC4)cn3)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR6 P51684 1/20 0.43
▸ CDK5 Q00535 4/20 0.40
▸ CDK5R1 Q15078 4/20 0.40
▸ TEAD1 P28347 1/20 0.37
▸ YAP1 P46937 1/20 0.37
▸ BMP1 P13497 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MMP1 P03956 2/20 0.35
▸ MMP9 P14780 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29438872 1.00 CCR6 (0.43) CCR6CDK5CDK5R1TEAD1YAP1
SCHEMBL22718447 0.97 CCR6 (0.44) CCR6CDK5CDK5R1TEAD1YAP1
SCHEMBL29648363 0.92 CCR6 (0.41) CCR6CDK5CDK5R1TEAD1YAP1
SCHEMBL24496211 0.92 CCR6 (0.41) CCR6CDK5CDK5R1TEAD1YAP1
SCHEMBL22843436 0.88 TEAD1 (0.40) CCR6TEAD1YAP1MAPTMEN1
SCHEMBL29438915 0.88 TEAD1 (0.49) CCR6TEAD1YAP1BMP1LMNA
SCHEMBL22718251 0.88 TEAD1 (0.49) CCR6TEAD1YAP1BMP1LMNA
SCHEMBL29438917 0.88 TEAD1 (0.49) CCR6TEAD1YAP1BMP1LMNA
SCHEMBL22718287 0.87 CDK5 (0.38) CCR6CDK5CDK5R1TEAD1YAP1
SCHEMBL31331755 0.86 CDK5 (0.41) CCR6CDK5CDK5R1PIK3CAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577208-B2 TEAD inhibitors and uses thereof EHE Foundation (US) 2026-03-17 — — US disclosed
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2024-03-14 — — US disclosed
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2022-08-11 — — US disclosed
CN-114466839-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2022-05-10 — — CN disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed
WO-2020243415-A2 TEAD INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2020-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251048-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885CDK5 301/4885CDK5R1 929/4885
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CCR6 4335/4885CDK5 301/4885CDK5R1 929/4885
US-20240083854-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885CDK5 301/4885CDK5R1 929/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 CCR6 4335/4885CDK5 301/4885CDK5R1 929/4885
US-12577208-B2 TEAD inhibitors and uses thereof BRCA1, BRAF, MEN1 CCR6 2313/4885CDK5 2566/4885CDK5R1 2810/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 CCR6 4335/4885CDK5 301/4885CDK5R1 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback